

Claim 45, line 2, change "diseases are" to --disease is-- and change "and" to --or--.

Rewrite the claims as follows.

E3
1 (amended). A modified human TNF α molecule capable of raising neutralizing antibodies towards unmodified human TNF α following administration of said modified TNF α to a human host, wherein one or more peptide fragments of the human TNF α molecule has been substituted by one or more peptides [known to contain] containing immunodominant T cell epitopes or a truncated form of said molecule containing the immunodominant epitope and one or both flanking regions of the human TNF α -molecule comprising at least one TNF α B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front β -sheet, in any one of the connecting loops, [and/or] or in any one of the B', I or D strands of the back β -sheet.

E4
8 (amended). Modified human TNF α molecule according to claim 1, wherein the substitution comprises segments of the H and I strands and the entire connecting loop [, preferably amino acids 132 to 152].

REMARKS

Claims 1, 2, 4-16, 19, and 26-42 remain active. Claims 29-31, 33-39, 46, 48, and 49 were withdrawn from consideration pursuant to restriction under §121.

The abstract is revised as required.

The specification is revised to insert the appropriate sequence identification number ("SEQ ID NO") at pages 15, 16, 40, 43, and 50. Neither sequence on page 37 has a